Stocks in play: Imaflex Inc.
Reports consolidated financial results for the third quarter ended September 30, 2022 and provides a business update. YTD 2022 net income up 28.3% to $8.6 million (EPS: $0.17), versus $6.7M (EPS: $0.13) in 2021; Q3 2022 net income up 12.6% to $3.1 million (EPS: $0.06), versus $2.8 million (EPS: $0.05) in 2021; Q3 2022. Imaflex Inc. shares V.IFX are trading unchanged at $1.50.
Read:
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates
Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America
Fresher, Healthier Food Options Coming Soon to an Airplane Tray Near You
Airline Industry Wooing Back Customers with Enhanced, Healthier Menu Options